The application of a half-life extended form of FGF21 (FGF21-PEG) has been demonstrated to normalize plasma glucose levels in streptozotocin-treated mice, a model of type 1 diabetes mellitus (T1DM), without reinstating pancreatic β-cell function. Here, FGF21 is linked to diabetes mellitus.